# Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT

> **NCT00534989** · NA · COMPLETED · sponsor: **King Faisal Specialist Hospital & Research Center** · enrollment: 10 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Hodgkin Disease

## Interventions

- **PROCEDURE:** FDG PET

## Key facts

- **NCT ID:** NCT00534989
- **Lead sponsor:** King Faisal Specialist Hospital & Research Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2013-02
- **Final completion:** 2013-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00534989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00534989, "Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00534989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*